focus -WSS

focus

author：knowledge 2025-08-28 13:04:16 - browse：7528

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Choosing scientific sides in the fight against Alzheimer's

hotspot

WSS

Second xenotransplant done with gene

Drug for rare kidney disease narrowly misses mark in clinical trial

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

The painfully weak evidence on taking collagen to treat arthritis

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

After affirmative action ruling, medical educators look to 'holistic review'

Wegovy cuts risk of cardiovascular events by 20%, study finds

Moonlake's readout produced a cash windfall. Risks remain

Microbiome research is starting to find links to chronic diseases

The cancer drug shortage isn’t new — and neither are the solutions

Senate HELP committee spars over health care workforce policies

Heart attack and stroke risk calculators need revising

‘The Bear’ and hospitality in hospitals

knowledge

Lessons Learned: This is why you network to find that industry job you want

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Ohioans vote in high

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

An Ebola outbreak presents a new mystery involving children

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

hotspot

explore

focus